ArticleMedical oncology (Northwood, London, England)2025
Cardio-oncology in focus: novel molecular signatures of lung adenocarcinoma-driven cardiac cachexia.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCardiac cachexia linked to lung adenocarcinoma (LCACC) is a clinically important yet under-researched issue in cardio-oncology. LCACC is caused directly by the progression of the tumor, unlike cardiotoxicity induced by therapy. We proposed that LCACC myocardium exhibits unique transcriptomic and immunometabolic profiles.
objectiveTo thoroughly analyze the molecular alterations in the myocardium associated with LCACC and pinpoint possible regulatory genes and therapeutic targets.
methodsWe conducted a comprehensive bioinformatics analysis using publicly accessible myocardial RNA-seq data (n = 4 + 4) from LCACC and control mice. The analyses comprised differential gene expression (DEG), immune deconvolution using xCell, gene set enrichment analysis (GSEA), weighted gene co-expression network analysis (WGCNA), and protein-protein interaction (PPI) networks.
resultsIn LCACC, the myocardium exhibited metabolic reprogramming characterized by increased oxidative phosphorylation (OXPHOS) and protein synthesis pathways, while cell cycle and inflammatory signaling (such as NF-κB) were downregulated. The analysis of immune profiles indicated a rise in fibroblasts and megakaryocyte-erythroid progenitors, while conventional dendritic and memory B cells were reduced. Five central genes (CCL2, CDC20, MKI67, CX3CR1, CXCL1) were discovered, grouped within chemokine signaling and cell division pathways, and linked to actionable upstream transcription factors, miRNAs, and possible drugs.
conclusionThis research offers the initial comprehensive map of transcriptomic and immunometabolic changes in LCACC. These results emphasize that LCACC involves active, regulated biological processes, indicating it is not just a passive result of cachexia, and they pave the way for further mechanistic and translational studies.
Indexed as
Identifiers
40759788What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.